ARTICLE | Clinical News
Telaprevir: Additional Phase IIa data
November 10, 2008 8:00 AM UTC
Additional data from the open-label Phase IIa C208 study showed that 1,125 mg of twice-daily telaprevir plus Copegus ribavirin and either Pegasys peginterferon alfa-2a or PEG-Intron peginterferon a...